articleJournal of Clinical InvestigationSep 8, 2014Closed access

The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss

Novo Nordisk (Denmark) · Gubra (Denmark) · +2 more institutions

PubMed
Indexed incrossrefdoajpubmed

Abstract

Liraglutide is a glucagon-like peptide-1 (GLP-1) analog marketed for the treatment of type 2 diabetes. Besides lowering blood glucose, liraglutide also reduces body weight. It is not fully understood how liraglutide induces weight loss or to what degree liraglutide acts directly in the brain. Here, we determined that liraglutide does not activate GLP-1-producing neurons in the hindbrain, and liraglutide-dependent body weight reduction in rats was independent of GLP-1 receptors (GLP-1Rs) in the vagus nerve, area postrema, and paraventricular nucleus. Peripheral injection of fluorescently labeled liraglutide in mice revealed the presence of the drug in the circumventricular organs. Moreover, labeled liraglutide…

Citation impact

913
total citations
FWCI
36.74
Percentile
100%
References
95
Citations per year

Authors

16

Topics & keywords

Keywords
  • Liraglutide
  • Endocrinology
  • Area postrema
  • Proopiomelanocortin
  • Internal medicine
  • Circumventricular organs
  • Arcuate nucleus
  • Hypothalamus
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding